This study compares two treatments for children with low-grade glioma (LGG), a type of brain tumor. The study has two groups: one group gets **tovorafenib**, a new medicine, and the other gets standard chemotherapy, which is a common cancer treatment using strong drugs. The study will see which treatment works better, is safer, and easier to handle for the patients. About 400 patients will be part of this study.

To join, kids must be under 25 years old and have a specific change in their tumor called an RAF alteration. They also need to have a type of tumor called glioma or glioneuronal tumor, with at least one measurable tumor area.

The study will last until the tumor grows, or there are bad side effects, or if the patient decides to stop. Doctors will check the tumor's size using special guidelines called RANO criteria. The study is open to patients worldwide, and it’s important for the doctors to discuss any changes in symptoms with the study team.

• Participants will be in the study until the tumor progresses, side effects occur, or they choose to stop.
• Participants will receive either tovorafenib or a standard chemotherapy regimen.
• Doctors must confirm tumor progression before changing treatment.